Skip to content

Evaluating Whether Non-Invasive Brain Stimulation (tDCS) Can Reduce Symptoms in People with Major Depression (Without Psychotic Symptoms)

EFFECT OF NEUROMODULATION THERAPY- TRANSCRANIAL DIRECT CURRENT STIMULATION [tDCS] IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER [MDD] WITHOUT PSYCHOTIC SYMPTOMS: A PROSPECTIVE, OPEN LABELED, RANDOMISED CLINICAL TRIAL. - NIL

Status
Recruiting
Phases
Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2025/06/089508
Enrollment
82
Registered
2025-06-25
Start date
Unknown
Completion date
Unknown
Last updated
2025-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: F321- Major depressive disorder, singleepisode, moderate

Interventions

Intervention1: transcranial direct current stimulation: tDCS works by applying a low electrical current to specific brain areas, especially the dorsolateral prefrontal cortex (DLPFC), which plays a cr

Sponsors

Dr Roli Gupta
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Male or Female patients in the age group of 18 to 65 years. Diagnosis of Major Depressive Disorder (MDD) according to ICD 11 criteria. Major Depressive Disorder, indicated by a baseline HAM D21 score (for example ,more than 8) Currently receiving SSRI treatment or about to initiate SSRI treatment. Ability to provide informed consent and comply with study procedure. Subjects with Unipolar Depression.

Exclusion criteria

Exclusion criteria: History of bipolar disorder, schizophrenia, or any psychotic disorders. Neurological conditions, such as epilepsy, history of seizures, or significant head injury. Presence of metallic implants or devices in the head that contraindicate tDCS. Pregnancy or breastfeeding women. Unstable or severe medical conditions that might interfere with participation or assessment. Subjects with pre existing cognitive impairment or mental retardation. Subjects with history of substance use (except nicotine and/or caffeine)

Design outcomes

Primary

MeasureTime frame
Change in depression severity, assessed using the Hamilton Depression Rating Scale (HAM-D21) at baseline, week 3, and week 6. Timepoint: at baseline, 3 weeks and 6 weeks

Secondary

MeasureTime frame
Feasibility & tolerability of tDCS as an add-on therapy. Response in the Indian population, contributing to personalized treatment approaches. Timepoint: at baseline, 3 weeks & 6 weeks

Countries

India

Contacts

Public ContactDr Roli Gupta

Shri B.M Patil Medical college, hospital and research centra

santoshramdurg@gmail.com9611281386

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026